These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28923834)

  • 1. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
    McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
    Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
    Doggrell SA
    Expert Opin Pharmacother; 2002 May; 3(5):625-8. PubMed ID: 11996640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF; Curran MP; Goa KL; Perry CM
    Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
    Evans M; Bain SC; Hogan S; Bilous RW;
    Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
    Riphagen IJ; Deetman PE; Bakker SJ; Navis G; Cooper ME; Lewis JB; de Zeeuw D; Lambers Heerspink HJ
    Diabetes; 2014 Aug; 63(8):2845-53. PubMed ID: 24677717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
    Miao Y; Ottenbros SA; Laverman GD; Brenner BM; Cooper ME; Parving HH; Grobbee DE; Shahinfar S; de Zeeuw D; Lambers Heerspink HJ
    Hypertension; 2011 Jul; 58(1):2-7. PubMed ID: 21632472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.